Gene doctoring: a method for recombineering in laboratory and pathogenic Escherichia coli strains by Lee, David J et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Microbiology
Open Access Methodology article
Gene doctoring: a method for recombineering in laboratory and 
pathogenic Escherichia coli strains
David J Lee*1, Lewis EH Bingle2, Karin Heurlier3, Mark J Pallen2, 
Charles W Penn1, Stephen JW Busby1 and Jon L Hobman3
Address: 1School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK, 2Division of Immunity and Infection, School of Medicine, 
University of Birmingham, Birmingham B15 2TT, UK and 3School of Biosciences, University of Nottingham, Sutton Bonington campus, Sutton 
Bonington, Loughborough, LE12 5RD, UK
Email: David J Lee* - D.Lee@bham.ac.uk; Lewis EH Bingle - l.e.bingle@bham.ac.uk; Karin Heurlier - karin.heurlier@nottingham.ac.uk; 
Mark J Pallen - pallenm@adf.bham.ac.uk; Charles W Penn - penncw@bioex1.bham.ac.uk; Stephen JW Busby - s.j.w.busby@bham.ac.uk; 
Jon L Hobman - jon.hobman@nottingham.ac.uk
* Corresponding author    
Abstract
Background: Homologous recombination mediated by the λ-Red genes is a common method for making
chromosomal modifications in Escherichia coli. Several protocols have been developed that differ in the
mechanisms by which DNA, carrying regions homologous to the chromosome, are delivered into the cell. A
common technique is to electroporate linear DNA fragments into cells. Alternatively, DNA fragments are
generated in vivo by digestion of a donor plasmid with a nuclease that does not cleave the host genome. In both
cases the λ-Red gene products recombine homologous regions carried on the linear DNA fragments with the
chromosome. We have successfully used both techniques to generate chromosomal mutations in E. coli K-12
strains. However, we have had limited success with these λ-Red based recombination techniques in pathogenic
E. coli strains, which has led us to develop an enhanced protocol for recombineering in such strains.
Results: Our goal was to develop a high-throughput recombineering system, primarily for the coupling of genes
to epitope tags, which could also be used for deletion of genes in both pathogenic and K-12 E. coli strains. To that
end we have designed a series of donor plasmids for use with the λ-Red recombination system, which when
cleaved in vivo by the I-SceI meganuclease generate a discrete linear DNA fragment, allowing for C-terminal tagging
of chromosomal genes with a 6 × His, 3 × FLAG, 4 × ProteinA or GFP tag or for the deletion of chromosomal
regions. We have enhanced existing protocols and technologies by inclusion of a cassette conferring kanamycin
resistance and, crucially, by including the sacB gene on the donor plasmid, so that all but true recombinants are
counter-selected on kanamycin and sucrose containing media, thus eliminating the need for extensive screening.
This method has the added advantage of limiting the exposure of cells to the potential damaging effects of the λ-
Red system, which can lead to unwanted secondary alterations to the chromosome.
Conclusion: We have developed a counter-selective recombineering technique for epitope tagging or for
deleting genes in E. coli. We have demonstrated the versatility of the technique by modifying the chromosome of
the enterohaemorrhagic O157:H7 (EHEC), uropathogenic CFT073 (UPEC), enteroaggregative O42 (EAEC) and
enterotoxigenic H10407 (ETEC) E. coli strains as well as in K-12 laboratory strains.
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Background
The λ-Red recombinase system can be used to introduce
mutations, deletions, or insertions into the E. coli chro-
mosome by recombining regions of homology carried on
short single-stranded oligonucleotides or large double-
stranded DNA molecules [1]. The λ-Red system consists of
three proteins, the gam, exo and bet gene products. When
expressed in the cell the Gam protein protects linear dou-
ble stranded DNA from degradation by the host RecBCD
complex. The Exo protein generates single stranded DNA
overhangs, which are substrates for recombination, cata-
lyzed by the Bet protein, with homologous regions of the
chromosome [2-7].
Several  λ-Red recombineering techniques have been
developed: Two in particular are of note, which differ in
the way that the target DNA is delivered into the cell. The
first technique, and arguably the most widely used, was
first described by Murphy [5] and later refined by Dat-
senko and Wanner [2]. In this method a plasmid is used
to express the λ-Red genes from an arabinose inducible
promoter. Strains expressing λ-Red are transformed, by
electroporation, with a dsDNA PCR product carrying an
antibiotic cassette flanked by short regions of homology
to the target gene. λ-Red mediated recombination occurs,
resulting in replacement of the targeted gene by an antibi-
otic resistance cassette. This cassette can then be excised by
FLP recombinase leaving a ~ 80 bp DNA scar in place of
the target gene.
The second technique, "gene gorging", designed by Her-
ring and co-workers [4], is a two plasmid method that also
utilizes the λ-Red system to generate recombinants. Gene
gorging eliminates the need to electroporate a dsDNA
fragment into cells, by supplying the regions of homology
to the target gene on a donor plasmid that also contains a
DNA recognition site for the Saccharomyces cerevisiae I-SceI
endonuclease. The donor plasmid and the recombineer-
ing plasmid, pACBSR (which carries the λ-Red and I-SceI
endonuclease genes, under the control of an araBAD pro-
moter), are transformed into the recipient strain. Upon
arabinose induction, I-SceI cleaves the donor plasmid,
providing a linear dsDNA target for the λ-Red system. The
obvious advantage of this system is that multiple copies of
the homologous DNA are present in the bacterial cell,
which increases the number of potential recombination
events. The frequency of recombination for gene gorging
is reported to be 1-15%, eliminating the absolute require-
ment for an antibiotic resistance marker to select for
recombinants.
We have used both systems for making gene knockouts
and gene fusions in laboratory E. coli strains. However, we
have had less success with these methods in pathogenic
strains such as the O157:H7 Sakai strain [8], and virtually
no success in the CFT073 UPEC [9], the O42 EAEC [10]
and the H10407 ETEC [11] strains. Since techniques such
as transduction by P1 phage are incompatible with many
pathogenic strains, due to extensive surface antigens that
block access to the phage receptor [12], gene deletions
have to be made directly in the strain.
Our aim in this study was to establish a high-throughput
recombineering system, with particular emphasis on the
ability to couple epitope tags to genes, which is compati-
ble, without modification, for use in a wide range of lab-
oratory and wild-type E. coli strains. We have achieved this
by enhancing the two-plasmid system of Herring and co-
workers, making three key modifications. First, a set of
donor plasmids have been generated that readily facilitate
the deletion of genes or the C-terminal coupling of genes
to epitope tags. Second, the inclusion of the sacB gene on
the donor plasmid allows for the counter-selection of all
but true recombinants. Third, the inclusion of an I-SceI
recognition site on a derivative of the recombineering
plasmid, called pACBSCE means that the plasmid is effec-
tively 'self-cleaving' upon induction of I-SceI and λ Red
genes. Hence cells receive a burst of λ-Red before pACB-
SCE is lost, which is sufficient to induce recombination
but limits the exposure of cells to λ-Red function. Pro-
longed exposure to λ-Red activity is undesirable as it can
cause unwanted secondary chromosomal modifications
in both K-12 and pathogenic E. coli strains [13-15]. We
have termed this method Gene Doctoring, abbreviated to
G-DOC (Gene Deletion Or Coupling), and we have dem-
onstrated its versatility by deleting and coupling genes to
epitope tags in pathogenic and laboratory E. coli strains.
Results and Discussion
Current techniques for recombineering in laboratory and 
pathogenic Escherichia coli strains
A. electroporation of linear DNA fragments
The method first described by Murphy [5], later refined by
Datsenko and Wanner [2], of electroporating linear dou-
ble stranded DNA fragments into cells that are then targets
for homologous recombination by the λ-Red system, is
reported to promote a very low recombination efficiency
in E. coli K-12 strains: approximately 1 in every 3.5 × 106
E. coli K-12 MG1655 cells that survive electroporation [4].
Despite this low frequency, we routinely identify between
10-50 MG1655 recombinants per experiment, however,
since we use approximately 1 × 109 MG1655 cells per elec-
troporation [16], the identification of only 10-50 recom-
binants indicates that in our hands the recombination
efficiency is approximately 1 in every 3.5 × 107 cells, 10
times less than reported.
Despite consistently attaining recombinants in MG1655
using this system we have had virtually no success in path-
ogenic strains. Since the low recombination frequency ofBMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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the system has been attributed to the inefficient uptake of
linear dsDNA fragments during electroporation [4], we
determined whether the inefficiency of this system for
recombination in pathogenic strains was due to a reduced
capacity to uptake DNA by electroporation. Thus, we
compared the transformation frequencies of MG1655,
O42, CFT073 and O157:H7 Sakai cells when transformed
by electroporation with different plasmids. Cells in the
exponential phase of growth were transformed by electro-
poration as previously described [2] with either: pUC18
[17], 2,700 bp (high copy number plasmid), conferring
ampicillin resistance; pKD46 [2], 6,300 bp (medium copy
number), conferring ampicillin resistance; pACBSR [4],
7,300 bp (medium copy number), conferring chloram-
phenicol resistance; pRW50 [18], 16,500 bp (low copy
number), conferring tetracycline resistance. Cells were
then plated onto Lennox broth (LB) agar plates supple-
mented with appropriate antibiotics, incubated for 20
hours at 37°C and the number of colonies counted. Table
1 shows the transformation frequencies of the pathogenic
strains by each plasmid, expressed as a percentage of the
transformation frequency of MG1655. It is clear that the
transformation frequencies of the pathogenic strains are
dramatically lower than for MG1655, particularly for
strains CFT073 and O42. Considering that we expect
approximately 10-50 recombinants in MG1655, such low
electroporation efficiencies could explain why using this
technique in pathogenic strains results in minimal suc-
cess.
Since the Datsenko and Wanner system relies upon the
introduction of PCR generated DNA into cells and not
plasmids that have been isolated from an E. coli K-12
strain, we re-examined the DNA uptake efficiencies of the
strains when transformed with a PCR generated version of
the plasmid, pUC18. We reasoned that plasmids isolated
from a K-12 strain may be subject to host restriction-mod-
ification systems in pathogenic strains, hence, using a
PCR-generated pUC18 derivative would not only more
closely resemble the conditions used by Datsenko and
Wanner, but also allow us to monitor the transformation
efficiencies by means of the acquired ampicillin resistance
due to pUC18 plasmid uptake. Thus, we amplified pUC18
by PCR and then incubated the reaction with DpnI, which
specifically digested the methylated template plasmid and
not the PCR generated product. The PCR generated
pUC18 plasmid (pUC18PCR) was then transformed into
MG1655, CFT073, O157:H7 Sakai and O42 by electropo-
ration. The results (table 1) show that the transformation
frequency of the pathogenic strains by pUC18PCR was
slightly improved when compared with MG1655,
although the overall transformation frequency remains
far lower than MG1655. The overall number of MG1655
colonies identified after transformation with pUC18 or
pUC18PCR was comparable. Thus, the electroporation
step is likely to be the primary reason for the poor effi-
ciency of this system in pathogenic E. coli strains. This
shortcoming was alleviated somewhat by Murphy and
Campellone [15] who developed an improved electropo-
ration based protocol for recombineering in E. coli EHEC
and EPEC strains. However, we have had mixed success
using this protocol, particularly when recombineering in
EAEC and UPEC strains, where no increase in recombina-
tion frequency was observed.
B. Two-plasmid recombineering
The two plasmid gene-gorging method described by Her-
ring and co-workers [4] has an immediate advantage for
recombineering in pathogenic strains since the method
does not rely upon efficient electroporation as a means of
introducing target DNA into the cell. Instead, the target
DNA is flanked by recognition sites for the meganuclease
I-SceI on a donor plasmid that is transformed into cells
along with the recombineering plasmid, pACBSR, which
carries I-SceI and the λ-Red genes whose expression is con-
trolled by an arabinose inducible promoter. Induction of
I-SceI results in donor plasmid cleavage, generating the
linear dsDNA target, which is a substrate for λ-Red gene
products. Herring and co-workers disrupted chromo-
somal genes by introducing amber mutations, using long
regions of homology to the chromosome and reported
that the recombination frequency for gene gorging was
between 1-15%.
To introduce epitope tags at the carboxyl terminus of
chromosomal genes and, crucially, to maintain a high-
throughput system, we chose to amplify the epitope tag by
PCR using oligonucleotide primers that contained 40 bp
of homology to the chromosomal gene of interest, rather
than sequentially cloning regions of homology to either
side of the epitope tag. We reasoned that since short
homologous sequences had already been successfully uti-
lised for recombineering by Datsenko and Wanner, [2]
this strategy could be adapted for epitope tagging. The
amplified DNA product was cloned into pBR322, modi-
fied so that the PCR product would be flanked by two rec-
ognition sites for I-SceI. The resulting construct was co-
transformed, along with pACBSR, into MG1655 cells and
gene gorging experiments performed as described by Her-
ring and co-workers [4]. The results of the experiments
Table 1: Electroporation efficiencies of E. coli strains
MG1655 O157:H7 Sakai CFT073 O42
pUC18 100 15 3 0.15
pKD46 100 5 2 0.26
pACBSR 100 2.8 1.5 0
pRW50 100 1.2 1.1 0
pUC18PCR 100 57 15 1BMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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(not shown) indicated that the recombination efficiency
using short regions of homology was very poor; several
hundred colonies recovered after gene gorging were
screened by PCR and the frequency of recombination was
found to be 0.01-0.05%, far less than the 1-15% reported
by Herring and co-workers.
To improve the identification rate of recombinants we
modified the technique by including a kanamycin cassette
adjacent to the epitope tag on the pBR322 based donor
plasmid. We reasoned that after in vivo digestion of the
donor plasmid, the ampicillin cassette carried on pBR322
would be lost and kanamycin resistance would only be
maintained if a successful recombination event had
occurred. Hence after gene gorging, cells were plated onto
LB agar plates containing kanamycin, and the next day
colonies were replica plated onto LB plates containing
either ampicillin or kanamycin. These colonies were
screened for candidates which were kanamycin resistant
and ampicillin sensitive, indicative of donor plasmid loss
and kanamycin cassette retention as a result of recombi-
nation with the chromosome. However, this approach
proved to be problematic, since unless the in vivo cleavage
rate of the donor plasmid by I-SceI approaches 100% effi-
ciency, the ampicillin and kanamycin cassettes are still
present on the donor plasmid in the cell, since the plas-
mid is present in multi-copy, rendering positive selection
ineffective. Typically we screened up to 30,000 colonies
by replica plating, identifying no more than 5 colonies
with the correct phenotype. Taken together these results
demonstrate that a more effective technique, that is both
rapid and reliable, is required to introduce epitope tags
onto the chromosome of pathogenic E. coli strains.
Gene Doctoring
To address this requirement we have developed an
enhanced version of the two-plasmid gene gorging sys-
tem. Our method, termed Gene Doctoring (G-DOC),
facilitates the coupling of genes to epitope tags or the dele-
tion of chromosomal genes and increases the rate of iden-
tifying recombinants. We have generated a suite of pDOC
plasmids which allow for the deletion of chromosomal
genes, or the coupling of chromosomal genes to a 6 × His,
a 3 × FLAG, a 4 × ProteinA or a GFP tag. The pDOC plas-
mids carry the sacB gene, which allows for the counter-
selection of cells still harbouring donor plasmid, thus
eliminating the need for screening post recombination.
Using this system we routinely identify more than 100
recombinants per experiment in both laboratory and
pathogenic E. coli strains, using short regions of homology
to the chromosome, thus maintaining both a high-
throughput and broad-range compatibility system.
G-DOC plasmids
The pDOC plasmids are derived from pEX100T, a
medium copy number plasmid which carries ampicillin
resistance and the B. subtilis sacB gene [19]. We have intro-
duced different DNA sequences into the pEX100T I-SceI
restriction sites to create a suite of plasmids, schematic
diagrams of which are shown in Figure 1. The cloning
plasmid, pDOC-C, has a large cloning region (CR)
flanked by two I-SceI recognition sites. The DNA sequence
of pDOC-C, from 100 bp upstream of the left-hand I-SceI
site to 100 bp downstream of the right-hand I-SceI site is
shown in Figure 2, panel A. The template plasmid, pDOC-
K, carries a kanamycin resistance cassette flanked by Flp
recombinase recognition sites (Flp1 and Flp2). On either
side of this region are 2 cloning regions (CR1 and CR2).
The other template plasmids, pDOC-H, pDOC-F, pDOC-
P and pDOC-G are derivatives of pDOC-K that have the
coding sequence for a 6 × His, 3 × FLAG, 4 × Protein A and
GFP tag respectively, immediately downstream of CR1.
Figure 2; panel B, shows the DNA sequence common to
all of the pDOC template plasmids, from 100 bp
upstream of the left-hand I-SceI site to 100 bp down-
stream of the right-hand I-SceI site. The template plasmids
differ between the CR1 and FLP1 sequences: this region is
outlined by an open box in the figure. The DNA sequence
proceeds through CR1, along the respective DNA
sequence for each plasmid within the open box, and into
the FLP1 sequence below. The plasmid pDOC-K has 30 bp
of DNA sequence prior to FLP1. The plasmid pDOC-H has
the coding sequence for the 6 × His tag and a stop codon
followed by a short DNA sequence leading into the FLP1
site. The first 10 codons of the 3 × FLAG, ProteinA and
GFP tags are shown, followed by the stop codon and short
DNA sequences leading into FLP1 site. Other features
indicated on the DNA sequences of the pDOC plasmids in
Figure 2 are described in the G-DOC recombineering pro-
tocol below. The full DNA sequence of each pDOC plas-
mid is provided in Additional file 1 and is also available
from GenBank, accession numbers GQ88494-
GQ889498.
G-DOC recombineering protocol
For generating gene:epitope tag fusions, the epitope tag
and kanamycin cassette are amplified by PCR, using the
relevant pDOC plasmid as a template. A schematic out-
line of the cloning strategy for generating gene:epitope tag
fusions is shown in Figure 3, panel A. The clockwise
primer used for the PCR amplification is designed so that
it contains between 25-50 bp of homology to the 3' end
of the target gene (H1), not including the stop codon, fol-
lowed by 20 bp of sequence which anneals to the epitope
tag sequence on the pDOC plasmid. This should be
designed so that, after recombination with the target gene
on the chromosome, the gene will be in frame with the
coding sequence of the epitope tag. The downstream
primer is designed so that it contains 25-50 bps of homol-
ogy to the DNA sequence immediately downstream of the
target gene (H2) and the primer sequence P-REV. The two
primers are also designed with a restriction site at the 5'BMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
Page 5 of 14
(page number not for citation purposes)
The pDOC donor plasmids Figure 1
The pDOC donor plasmids. Circular representation of the pEX100T plasmid showing the location of the origins of replica-
tion, the sacB gene and the ampicillin resistance gene. Below is a linear representation of the pDOC plasmid inserts, showing 
the I-SceI restriction sites, cloning regions (CR, CR1 and CR2), the Flp recognition sites flanking the kanamycin resistance cas-
sette (KanR) and the location of the epitope tags in plasmids pDOC-H, pDOC-F, pDOC-P and pDOC-G.
pEX100T
ampR sacB
OriT pMBI Ori
pDOC-C
I-SceI I-SceI
CR
pDOC-K
I-SceI
CR 2
Flp1
KanR
Flp2 I-SceI
CR 1
pDOC-H
pDOC-F
pDOC-P
pDOC-G
6xHis
3xFLAG
Protein A
GFPBMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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DNA sequences of the pDOC plasmids Figure 2
DNA sequences of the pDOC plasmids. (A) DNA sequence of pDOC-C insert. The location of sequencing primer 
annealing sites is indicated (SS1 and SS2). The I-SceI recognition sites are shown flanking the cloning region. (B) DNA 
sequences of the pDOC-K, pDOC-H, pDOC-F, pDOC-P and pDOC-G inserts. Sequences specific to each plasmid are shown 
in the open box. The first codon of the epitope tags are highlighted in grey, and the stop codons are indicated. The following 
primer annealing sites are indicated: SS1 and SS2, used to sequence plasmid derivatives pre-recombination; K-FWD, used for 
amplifying PCR products from pDOC-K for generating gene deletions; CC1 and CC2, used for generating PCR products in 
order to confirm recombination; P-REV, used to generate PCR products for cloning into pDOC-C pre-recombination. The Flp 
recognition sequences are shown (Flp1 and Flp2), flanking the kanamycin cassette. The cloning regions, CR1 and CR2 are 
shown, adjacent to the I-SceI recognition sites.
 S1  > 
TATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTC
       I-SceI                    EcoRI   HindIII BamHI SmaI  KpnI                    EcoRV    XhoI SacI   NdeI   NheI      SalI   SpeI 
TAGGGATAACAGGGTAATCGATGAATTCAAGCTTGGATCCCGGGTACCCACAGTAGATATCCTCGAGCTCATATGCTAGCGTCGACTA
       I-SceI                    
GTAGGGATAACAGGGTAATGAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCG
        < S2
CCTTGCAGCACATCC
          S1 > 
TATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTC
    CR1 
     I-SceI                      EcoRI  HindIII BamHI SmaI KpnI
TAGGGATAACAGGGTAATCGATGAATTCAAGCTTGGATCCCGGGTACC  
    K-FWD >   
pDOC-K   TAGGACCGGTCAATTGGCTGGAGCTGCTTC
     Stop
pDOC-H   CACCATCACCATCACCATTAAACCGGTCAATTGGCTGGAGCTGCTTC
                                               Stop
pDOC-F   GACTACAAAGACCATGACGGTGATTATAAA..............TAATGTAGGCTGGAGCTGCTTC
                                               Stop
pDOC-P   AGCGGTGAAGCTCAAAAACTTAATGACTCT..............TAATGTACCGGTCAATTGGCTGGAGCTGCTTC
                                               Stop
pDOC-G   AGCAAGGGCGAGGAGCTGTTCACCGGGGTG..............TAAACCGGTCAATTGGCTGGAGCTGCTTC
            Flp 1                          
GAAGTTCCTATACTTTCTAGAGAATAGGAACTTCGGAATAGGAACTTCAAGATCCCCCACGCTGCCGC
         < CC1                   
AAGCACTCAGGGCGCAAGGGCTGCTAAAGGAAGCGGAACACGTAGAACTTAAG........KANAMYCIN CASSETTE......... 
     CC2 >
CGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAGCTTCAAAAGCGCTCTGAAGTTCC
        C R 2  
   Flp 2             < P-REV XhoI  SacI NdeI NheI      SalI    SpeI                        
TATACTTTCTAGAGAATAGGAACTTCGGAATAGGAACTAAGGAGGATATTCATATCTCGAGCTCATATGCTAGCGTCGACTAGTAGGG
     I-SceI
ATAACAGGGTAATGAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGC
< S2
AGCACATCC
B 
A BMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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end, so that, after amplification by PCR, the DNA product
can be cloned into the cloning region of pDOC-C,
between the two I-SceI sites.
For generating gene deletions, the kanamycin cassette
from pDOC-K, is amplified by PCR. A schematic outline
of the cloning strategy for generating gene deletions is
shown in Figure 3, panel B. The clockwise primer used for
the PCR amplification is designed so that it contains
between 25-50 bp of homology to the DNA immediately
upstream of the start of the gene (H3), followed by 20 bp
of sequence which anneals to the K-FWD sequence on
pDOC-K. The anti-clockwise primer is designed so that it
contains 25-50 bps of homology to the 3' end of the gene
(H4) and the primer sequence P-REV. Again, the two
primers are designed with 5' restriction sites for cloning
the DNA product into pDOC-C.
Alternatively, when longer regions of homology to the
chromosome are required, sequential cloning steps can be
performed, utilising the multiple cloning sites to intro-
duce long regions of chromosomal homology upstream
and downstream of the kanamycin cassette and epitope
tag. In this case we recommend sequencing the cloned
homology regions, post cloning and before recombineer-
ing, using priming sequences S1 and S2 (highlighted in
Figure 2: primers D58794 and D58793).
The next step is to transform the pDOC donor plasmid
into the recipient strain with the recombineering plasmid,
which expresses I-SceI and the λ-Red gene products. A
schematic protocol, outlining the key steps in generating
recombinants is shown in Figure 4. We have modified the
recombineering plasmid, pACBSR, used by Herring and
co-workers [4] by introducing an I-SceI recognition site
adjacent to the replication origin of the plasmid: we have
called this plasmid pACBSCE. Upon arabinose induction,
a burst of I-SceI and λ-Red expression occurs; I-SceI
cleaves the donor plasmid resulting in generation of the
substrate for λ-Red mediated recombination. In addition,
I-SceI also cleaves the pACBSCE recombineering plasmid,
resulting in loss of plasmid and loss of λ-Red expression,
thus avoiding prolonged λ-Red activity, which can result
in unwanted chromosomal modification [13-15]. Recom-
bination occurs between homologous regions on the lin-
ear DNA substrate and the chromosome, transferring the
kanamycin cassette, and in the case of gene:coupling, the
epitope tag, onto the chromosome (Figures 3 and 4).
Recombinant clones are selected for by growing cells on
LB agar plates containing kanamycin and sucrose: only
Schematic of pDOC based recombination Figure 3
Schematic of pDOC based recombination. PCR products are generated for gene coupling (A) or for gene deleting (B) 
and cloned into pDOC-C. Homologous regions (H1-4) on the PCR product recombine with the target gene on the chromo-
some. Recombinant clones are then checked by PCR using primers annealing to the CC1 and CC2 sequences, and sequences 
adjacent to the homology regions.
pDOC plasmid 
template 
PCR product 
cloned into 
pDOC-C 
Chromosome 
recombinant 
A B 
Epitope tag 
P-REV 
H2
H2 H1
H1 H2
H1
CC1
CC2
H1 H2
Target Gene
Recombination with chromosome 
K-FWD 
P-REV 
H3
H4
H4 H3
H3 H4
H3 H4
CC1
CC2
Target Gene
Recombination with chromosome 
￿
￿
￿
￿
￿
￿
￿
￿BMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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true recombinants, which have lost the sacB gene due to
donor plasmid loss and have retained the kanamycin cas-
sette due to recombination, are able to survive and grow
on this medium. Examination of recombinants, to ensure
that the correct chromosomal modification has been gen-
erated, is achieved by amplifying the target region by PCR,
using primers that anneal adjacent to the homology
regions (H1-4 in figure 3) and chromosomal check prim-
ing sequences CC1 and CC2 (Figure 2, panel B and Figure
3). Once recombination has been confirmed, the kanamy-
cin cassette can be excised from the chromosome using
the Flp recombinase sites, as described previously. [2]
G-DOC validation
To test our system we designed oligonucleotides to couple
the rsd and yacL genes to the 3 × FLAG epitope tag. One
primer contained homology to the first 7 codons of the 3
× FLAG sequence, 40 bp of homology to the 5' end of the
target gene, excluding the stop codon, and an EcoRI
restriction site (primer D61350 for rsd and D61352 for
yacL). The second primer contained homology to the P-
REV sequence, 40 bp of homology to the chromosome,
immediately downstream of the target gene primer and a
KpnI restriction site (D61351 for rsd  and D61353 for
yacL). DNA fragments generated by PCR using pDOC-F as
G-DOC recombineering Figure 4
G-DOC recombineering. The pDOC donor plasmid and the recombineering plasmid pACBSCE are co-transformed into 
the recipient strain. Arabinose induction promotes expression of the λ-Red gene products and I-SceI. I-SceI generates a linear 
DNA fragment form the donor plasmid that is a substrate for recombination with the chromosome mediated by the λ-Red 
system. Recombinants are selected by the ability to survive and grow on LB supplemented with kanamycin and sucrose.BMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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a template were cloned into pDOC-C, which was subse-
quently co-transformed with pACBSCE into K-12
MG1655, EHEC O157:H7 Sakai and UPEC CFT073 cells.
The Gene Doctoring protocol was followed and the results
are reported in table 2. For both genes, in all three strains,
a large number of colonies were identified with a kanamy-
cin resistant, sucrose insensitive phenotype. After PCR
analysis of the relevant chromosomal region (using
primer pairs D57786 (CC1) and D61354, and D57785
(CC2) and D61355 for rsd and D57786 and D61356, and
D57785 and D61357 for yacL) the vast majority of candi-
dates were found to be true recombinants and in each
case, more than 90% were sensitive to both ampicillin
and chloramphenicol, indicating loss of both pDOC
donor and pACBSCE plasmids. Where a candidate was
found to have the wild-type form of the gene after PCR
verification, we assumed that the kanamycin cassette had
inserted into a different part of the chromosome, since we
were unable to isolate any donor plasmid DNA from cells
using standard plasmid isolation techniques. Hence, for
each gene, in each strain, more than 150 recombinants
were identified that had the correct chromosomal modifi-
cation and were free of the recombineering plasmid
pACBSCE.
To test the effectiveness of recombination using our
recombineering plasmid pACBSCE, compared with the
recombineering plasmid pACBSR, used by Herring and
co-workers [4] we repeated the gene coupling analysis of
the rsd gene. The results in table 3 show that more kan-
amycin resistant, sucrose insensitive recombinants were
identified in each strain when pACBSR was used as the
recombineering plasmid, with a comparable percentage
being free of pDOC donor plasmid, when compared to
using pACBSCE as the recombineering plasmid. However,
very few candidates had lost the recombineering plasmid,
and in strain CFT073, all of the recombinant candidates
still carried pACBSR, thus exposing cells to the potential
effects of excess of λ-Red expression and requiring addi-
tional steps to cure cells of the plasmid [4,13-15].
We have further validated the system by making several
gene deletions in both laboratory and pathogenic strains.
DNA fragments, generated by PCR amplification, using
pDOC-K as a template were cloned into pDOC-C, and the
resulting donor plasmids used for gene doctoring. To date
we have made deletions of the rpoS, fur, flhDC and soxS
genes in MG1655, O157:H7 Sakai, CFT073 and H10407
strains (data not shown).
Functionality of the epitope tags
To examine the functionality of the epitope tags we cou-
pled each to the Lac repressor protein in MG1655. The
experimental details and primer design for each recombi-
nation experiment are given in the methods section. For
each epitope tag we identified more than 200 candidates
that were kanamycin resistant, sucrose insensitive. After
verification by PCR amplification and DNA sequencing of
the chromosomal region (Figure 5; panel A), we tested the
functionality of the epitope tags. The LacI::3 × FLAG,
LacI::4 × ProteinA and LacI::GFP fusion proteins were ana-
lyzed by Western blotting. Whole cell extracts were sepa-
rated by SDS-PAGE and proteins transferred to
nitrocellulose membranes, which were then probed with
primary antibodies specific to the tag. The membranes
were then washed and probed with secondary antibodies
conjugated to horse-radish peroxidase. Figure 5; panel B,
shows an image of the membranes after exposure to X-ray
film; the fusion proteins are indicated. In a recent study
we validated the functionality of the LacI::3 × FLAG fusion
protein by isolating DNA fragments carrying LacI binding
sites from cells [20]. We also confirmed the fluorescence
of the LacI::GFP fusion protein, in whole cells using fluo-
rescent microscopy (data not shown). Finally, we tested
the integrity of the 6 × His fusion proteins by isolating the
protein fusion by affinity purification using nickel agarose
Table 2: Comparison of recombination efficiency of E. coli strains
KanR SucI
(A)
recombinants Plasmid free recombinants
(B)
% plasmid free recombinants (B/A)
rsd
MG1655 249 248 232 93
O157:H7 Sakai 193 193 184 95
CFT073 174 170 156 90
yacL
MG1655 287 286 258 90
O157:H7 Sakai 218 218 209 96
CFT073 209 205 192 92BMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
Page 10 of 14
(page number not for citation purposes)
affinity media (Qiagen). Purified proteins were analysed
by SDS-PAGE. Figure 5; panel C, shows a scanned image
of the SDS-PAGE gel on which the fusion protein is high-
lighted.
Conclusion
We have developed a version of the two-plasmid recom-
bineering system for generating chromosomal modifica-
tions in E. coli strains which, we have termed Gene
Doctoring. This method relies on homologous recombi-
nation, mediated by the λ-Red genes, of a linear DNA frag-
ment that is supplied in vivo by restriction of a pDOC
donor plasmid by I-SceI endonuclease. The identification
of recombinants is highly efficient and reproducible, since
counter-selection using the sacB  gene identifies true
recombinants. This eliminates the requirement for screen-
ing large numbers of candidates by PCR, which is both
costly and time consuming. In addition, we have made a
Table 3: Comparison of recombination efficiency using recombineering plasmids pACBSCE and pACBSR
KanR+SucI % free of pDOC donor plasmid % free of recombineering plasmid
Recombineering plasmid pACBSCE pACBSR pACBSCE pACBSR pACBSCE pACBSR
MG1655 249 320 94 93 97 9
O157:H7 Sakai 193 308 97 99 97 3
CFT073 174 234 91 93 99 0
Verification and functionality of chromosomal lacI::tag fusions Figure 5
Verification and functionality of chromosomal lacI::tag fusions. (A) Ethidum bromide stained agarose gel showing 
DNA amplified by PCR from the lacI fusion strains. Lanes 1 and 6 are DNA markers, lanes 2, 3, 4 + 5 show DNA derived from 
lacI::6 × his, lacI::3 × FLAG, lacI::ProteinA and lacI::GFP respectively. (B) Western blot analysis of tagged strains. Lanes 1, 4 and 7 
show protein standards. Lanes 2, 5 and 8 show wild-type MG1655. Lanes 3, 6 and 9 show the tagged strains. Lanes 1, 2 + 3 
were probed with antibody specific to the FLAG tag, lanes 4, 5 +6 were probed with antibody specific to ProteinA and lanes 7, 
8 + 9 were probed with antibody specific to GFP. (C) SDS-PAGE analysis of the affinity-isolation of LacI::6 × His. Proteins were 
stained with Coomassie blue. Lane 1 shows protein standards, lane 2, whole cell extract, lane 3, LacI::6 × His affinity-isolate.
A
B
C
1    2    3    4    5    6
1     2    3         4     5     6          7     8     9
1     2    3
lacI::3xFLAG lacI::PrA lacI::GFPBMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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modified recombineering plasmid, pACBSCE, which car-
ries a DNA recognition site for I-SceI in the origin of rep-
lication, meaning that recombinants are not over-exposed
to the potential mutagenic side-effects of the λ-Red gene
products.
The gene doctoring system is principally effective for
recombineering in different pathogenic E. coli strains,
which as we have demonstrated, are not particularly ame-
nable to chromosomal modification using existing sys-
tems. This system is designed to facilitate the coupling of
genes to epitope tags, though the deletion of genes can
also be readily achieved. We have demonstrated the versa-
tility of Gene Doctoring by deleting genes in both labora-
tory and pathogenic E. coli strains, in addition to coupling
several genes to epitope tags, and we have confirmed the
functionality of epitope tagged fusion proteins using bio-
chemical methods. We believe that the gene doctoring sys-
tem can be transferable to other bacteria, in which the
pDOC and pACBSCE plasmids are stable and will repli-
cate.
Methods
Strains
The E. coli strains used in this study were MG1655 K-12
strain [21], O157:H7 Sakai EHEC strain (derivative in
which the stx1 and stx2 genes were deleted by M. D. Gold-
berg, University of Birmingham, UK) [8], CFT073 UPEC
strain [9] O42 EAEC [10] and H10407 ETEC strains [11]
(from Ian R. Henderson, University of Birmingham, UK;
Sequenced by the Sanger Institute: unpublished).
Primers
The primers used in this study are listed in table 4.
Table 4: Primers used in this study
Name Sequence 5' - 3'
D55908 ATATGGTACCGACTACAAAGACCATGACGG
D55909 TGACGAGCTCTATACTTATAGGAGGAATCAAGG
D57236 CTAGGGATAACAGGGTAATCGATGAATTCAAGCTTGGATCCCGGGTAC
D57237 CCGGGATCCAAGCTTGAATTCATCGATTACCCTGTTATCCCTAGACGT
D57238 TCGAGCTCATATGCTAGCGTCGACTAGTAGGGATAACAGGGTAATGCA
D57239 TTACCCTGTTATCCCTACTAGTCGACGCTAGCATATGAGC
D57436 GATCGGTACCTAGGACCGGTCAATTGACGCGTCTTAAGGGAATTGCCAGCTGGGGCGC
D57437 GTCTCTTGATCAGATCTTGATCC
D57584 AATGGTACCAGCGGTGAAGCTC
D57585 GAATACCGGTACATTACCCGGCATCGTC
D57785 GAATCTTAAGTTCTACGTGTTCCGC
D57786 CATGCTGGAGTTCTTCGCCC
D58793 GGATGTGCTGCAAGG
D58794 TATGCTTCCGGCTCG
D59400 GCTGAATTCCAAACAGGATTTTCGCCTGC
D59401 GTCGGTACCCTGCCCGCTTTCCAGTC
D59402 GTCCTCGAGGTTGATGAAAGCTGGCTAC
D59403 GTAGCTAGCTCCGCCACATATCCTG
D59990 TAGGGTACCAGCAAGGGCGAGGAGC
D59991 TAGACCGGTTTACTTGTACAGCTCGTCC
D60111 CCACAGTAGATATCC
D60112 TCGAGGATATCTACTGTGGGTAC
D60113 CAGGTTTCCCGACTGGAAAGCGGGCAGCCGGGTACCCACCATCAC
D60114 AGCTAACTCACATTAATTGCGTTGCGCAATATCCTCCTTAGTTCC
D61347 CGTTGGTGCGGATATCTCGG
D61350 GACGAATTCTCTGCTGGTGCTTGACGCCGCCCGCGTCAAACATCCTGCTTACAAAGACCATGACGGTGAT
D61351 CAGGGTACCTGGGGCATTGAATGTAAATTACGCGTTAACAGCGCAGAACAATATCCTCCTTAGTTCC
D61352 GACGAATTCGCAGGTCGTGGCGGCTTACCGCAATTTCGTGCAGCAGAAGTACAAAGACCATGACGGTGAT
D61353 CAGGGTACCTAACGGCTCTGGCGGAGCTCCCAGGCTCCGCCAGATTTATAATATCCTCCTTAGTTCC
D61354 TACCTTGAGTTTCAACAGG
D61355 GATCCCGAATAAACGGTC
D61356 CAATCAACTGGAATTCGC
D61357 CGGAAGACTTAACCGACAGC
D61358 TAGGGATAACAGGGTAATGAGCGGAAATGGCTTACGAAC
D61359 GCCGCAGTCGAACGACCGAG
D61360 GTTGGCACTGATGAGGGTGT
D66425 CTCGAATTCGTAATCATGGTCATAGCTGTTTCCTG
D66426 CAGGAAACAGCTATGACCATGATTACGAATTCGAGBMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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Generation of pUC18PCR
The plasmid pUC18PCR was generated by PCR using
primers D66425 and D66426, with pUC18 used as a tem-
plate in the reaction. The two primers were designed so
that 35 bp complementary overhangs remained at each 5'
terminus of the amplicon, facilitating plasmid re-circular-
isation pre-transformation. The restriction enzyme DpnI
was then added to the reaction in order to digest specifi-
cally the methylated pUC18 template plasmid, leaving
only the PCR generated pUC18PCR intact.
Construction of the pDOC plasmids
The pDOC series of plasmids are based on the plasmid
pEX100T [19]. A schematic representation of the plasmids
is shown in Figure 2 and the entire DNA sequence of each
plasmid is provided in Additional file 1 and also on Gen-
Bank; nos.. The plasmid pDOC-F was constructed by
amplification of the 3 × FLAG DNA sequence, Flp recom-
binase target sites (Flp1 and Flp2) and the kanamycin cas-
sette from the plasmid pSUB11 [22], flanked by KpnI and
XhoI restriction sites, using the primers D55908 and
D55909. This amplicon was cloned into the pGEM-T Easy
cloning vector (Promega). The resulting plasmid was then
restricted with AatII and KpnI, and ligated with annealed
complementary oligonucleotides (D57236 and D57237),
designed to introduce an I-SceI site and a multi-cloning
region (CR1). This plasmid was then restricted with XhoI
and NsiI and ligated with annealed complementary oligo-
nucleotides (D57238 and D57239), designed to intro-
duce a second I-SceI site and a multi-cloning region
(CR2). The resulting plasmid was restricted with I-SceI,
and the fragment cloned into the I-SceI sites of the plas-
mid pEX100T.
To facilitate further plasmid construction, the 3 × FLAG
DNA sequence was removed from pDOC-F, and an AgeI
restriction site introduced immediately downstream of
the KpnI site. This was achieved by PCR amplification of
the DNA immediately downstream of the 3 × FLAG DNA
sequence, flanked by KpnI and BglII restriction sites using
primers D57436 and D57437. This fragment was then
cloned into the unique KpnI and BglII sites of pDOC-F,
effectively removing the 3 × FLAG DNA sequence. This
new plasmid, pDOC-K, retained the Flp recombination
target sites and the kanamycin cassette.
The plasmid pDOC-K was restricted with KpnI and AgeI,
and KpnI-AgeI flanked DNA harboring a 6 × His coding
sequence, the coding sequence of GFP (from Invitrogen
Emerald Green GFP gateway vector - V355-20; amplified
with primers D59990 and D59991) or the coding
sequence of ProteinA [23] (amplified using primers
D57584 and D57585), were ligated. This resulted in the
generation of the plasmids pDOC-H, pDOC-G and
pDOC-P respectively.
The plasmid pDOC-C was created by removing the Flp
recombinase sites and the kanamycin cassette from
pDOC-K, by digestion with KpnI-XhoI, and ligation with
annealed complementary oligonucleotides that intro-
duced a unique EcoRV site (D60111 and D60112).
Construction of pACBSCE
Plasmid pACBSR [4] was used as a template in PCR to cre-
ate pACBSCE, using the primers D61358 and D61359,
which anneal adjacent to the origin of replication.
D61358 contains the recognition sequence for I-SceI at
the 5' end. The resulting linearised plasmid, carrying an I-
SceI recognition site, was self-ligated using a Quick Liga-
tion Kit (NEB). Circularized plasmid was transformed
into TOP10 cells (Invitrogen) and plated onto LB agar
plates supplemented with chloramphenicol (35 μg/ml).
The plasmid was then checked by digestion with I-SceI
enzyme (N.E.B.), and sequenced using primer D61360.
Gene-doctoring protocol
Electrocompetent E. coli cells were transformed with the
recombineering plasmid, pACBSCE, and a pDOC donor
plasmid derivative and spread onto LB agar plates con-
taining 35 μg/ml chloramphenicol (for pACBSCE) and
200  μg/ml ampicillin and 50 μg/ml kanamycin (for
pDOC derivatives)(LBCAK agar plates). Colonies were rou-
tinely tested for maintenance of the sacB  gene on the
pDOC donor plasmid, by patching onto LBCAK agar plates
and LBCAK agar plates supplemented with 5% sucrose: col-
onies containing a functional sacB gene will be unable to
grow on plates supplemented with 5% sucrose. A single
fresh sucrose sensitive colony was inoculated into 1 ml of
LBCAK, supplemented with 0.5% Glucose, which was
added to prevent leaky expression of the λ-Red and I-SceI
genes from pACBSCE. Cultures were incubated with shak-
ing at 37°C for 2 hours. Cells were harvested by centrifu-
gation and re-suspended in 1 ml LB containing 0.5% L-
arabinose which was added to induce expression of the λ-
Red and I-SceI genes from pACBSCE. Note that antibiotics
were omitted from the growth medium at this stage. The
culture was incubated at 37°C, with vigorous shaking
until turbid (approximately 4-5 hours). Dilutions of the
culture were then plated on to LB agar plates containing
50 μg/ml kanamycin and 5% sucrose and incubated over-
night at 30°C. Kanamycin resistant, sucrose insensitive
recombinants were checked for donor plasmid loss by
patching onto LB agar plates containing 200 μg/ml ampi-
cillin and pACBSCE plasmid loss by patching onto LB agar
plates containing 35 μg/ml chloramphenicol. Recombi-
nation was confirmed by PCR and sequencing, using oli-
gonucleotide primers homologous to chromosomal DNA
flanking the modified region (sequencing provided by the
Birmingham Functional Genomics laboratory). Note: in
addition, dilutions of the culture were routinely plated
onto LB agar plates and LB agar plates supplemented withBMC Microbiology 2009, 9:252 http://www.biomedcentral.com/1471-2180/9/252
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200 μg/ml of ampicillin, to quantify the amount of donor
plasmid digestion by I-SceI and LB agar plates and LB agar
plates supplemented with 35 μg/ml chloramphenicol, to
quantify pACBSCE digestion by I-SceI.
Construction of pDOC derivatives for generating lacI gene 
fusions
Four different lacI  gene fusions were constructed in
MG1655, producing the following recombinant proteins;
LacI::6 × His, LacI::3 × FLAG, LacI::4 × ProteinA and
LacI::GFP. For the LacI::6 × His construct, two primers
were designed to amplify the 6 × his coding region and the
kanamycin cassette from pDOC-H: the first primer,
D60113, included 27 bp of homology to the C-terminus
of lacI, excluding the stop codon, and 18 bp homology to
pDOC-H and was designed so that the 6 × his sequence
was in frame with the lacI coding sequence. The second
primer, D60114 included 27 bp of homology to the
region immediately downstream of lacI, and homology to
the P-REV annealing sequence. These primers were used to
amplify the kanamycin resistance cassette, using pDOC-H
as a template, and a proof-reading thermostable DNA
polymerase that produces a blunt-ended amplicon. The
resulting fragment was blunt end ligated into the EcoRV
site of pDOC-C. The cloned region was sequenced using
primers D58793 and D58794, which anneal to the S1 and
S2 sites (Figure 2) in the pDOC-C plasmid. The resulting
plasmid was then used to tag the chromosomal lacI gene
in E. coli strain MG1655 by gene doctoring. Recombinants
were checked by PCR and sequencing using primers
D61347, which anneals within the lacI gene, and D57785,
which anneals to the CC1 sequence shown in Figure 2.
The lacI::3 × FLAG, lacI::4 × ProteinA and lacI::GFP gene
fusions were made using longer regions of homology to
the chromosome, cloned directly into the pDOC-F,
pDOC-P and pDOC-G cloning regions. The C-terminal
200 bp of the lacI gene, excluding the stop codon, was
amplified by PCR using primers D59400 and D59401,
and cloned into CR1 of the appropriate tagging vector, on
a EcoRI:KpnI fragment, arranged so that the coding
sequence of the gene was in frame with the epitope tag.
Next, a 200 bp region of the lacZ gene (codons 130-205)
was amplified by PCR using primers D59402 and D59403
and cloned into CR2 of the appropriate tagging vector, on
a XhoI:NheI fragment. The resulting plasmids were then
used to tag the chromosomal lacI gene in E. coli strain
MG1655 by gene doctoring. Recombinants were checked
by PCR and DNA sequencing as before.
Western blotting
Cells of strain MG1655lacI::3 × FLAG, MG1655lacI::4 ×
ProteinA and MG1655lacI::gfp were grown in LB medium
at 37°C to an OD650 of 1.2. Samples were taken and cell
extracts were separated on a SDS-PAGE gel. Proteins were
then transferred to a nitrocellulose membrane, which was
probed with antibodies specific for the FLAG peptide
(Sigma), ProteinA (Sigma) or GFP (Roche). The mem-
branes were then incubated with HRP-labeled anti-mouse
IgG (Sigma), and binding of antibody visualized by scan-
ning with a Syngene Gene Genius Bioimaging System.
Affinity isolation of LacI::6 × His
A 100 ml culture of strain MG1655lacI::6 × his was grown
in LB medium at 37°C to an OD650 of 1.2. Cells were har-
vested and re-suspended in 4 mls of lysis buffer (10 mM
Tris, 100 mM NaCl, 10% Glycerol). Lysozyme was added
to a final concentration of 400 μg/ml, and the mixture
incubated on ice for 30 minutes, with regular mixing.
After lysozyme treatment, the lysate was cleared by centrif-
ugation and the supernatant incubated with 200 μl of
NTA-Ni-agarose beads (Qiagen), on ice for 30 minutes.
The supernatant was then removed, and the beads washed
with 1 ml of wash buffer (10 mM Tris, 100 mM NaCl,
10% Glycerol, 10 mM Imidazole). LacI::6 × His was then
eluted from the beads with 100 μl of elution buffer (10
mM Tris, 100 mM NaCl, 10% Glycerol, 250 mM Imida-
zole).
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